NEUP — Neuphoria Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$3.84
+$0.05 (+1.32%)
Neuphoria Therapeutics Inc (NEUP) is a biotechnology company listed on NASDAQ. It is led by Spyridon Papapetropoulos M.D., Ph.D., based in 100 Summit Drive, Burlington, MA, United States, 01803, with about 7 employees. Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
Latest reported NEUP revenue for 2025-06-30 was $15.6M. Net income was -$369.6K. NEUP currently screens at market cap $23.6M.
Use this NEUP page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NEUP quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NEUP SEC filings page. Lician reads the product cache first so this HTML stays unique to Neuphoria Therapeutics Inc even when a live quote feed is slow.
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
NEUP Key Statistics
Market Cap
$23.56M
Volume
57,905
Previous Close
$3.91
Day Range
$3.90 – $4.01
P/B Ratio
0.79
EPS
-$0.23
Revenue
$15.65M
Net Income
-$369.63K
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-2.4%
Employees
7
NEUP Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $15.65M | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$369.63K | -$15.49M | -$21.38M |
| EPS (Diluted) | -$0.23 | -$18.62 | -$0.02 |
Total Assets
$28.59M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$14.21M
Operating Cash Flow
$77.23K
Free Cash Flow
$0.00
Neuphoria Therapeutics Inc Company Information
- Interim CEO & Executive Director
- Spyridon Papapetropoulos M.D., Ph.D.
- Headquarters
- 100 Summit Drive, Burlington, MA, United States, 01803
- Website
- www.neuphoriatx.com
- Phone
- 781 439 5551
- IPO / Founded
- 2024-12-23
- Sector
- Healthcare
- Industry
- Biotechnology